Technology ID
TAB-4600
Inhibition of Epoxide Hydrolase 1 in the Treatment of Cardiovascular Diseases
E-Numbers
E-144-2016-0
Lead Inventor
Edin, Matthew (NIEHS)
Co-Inventors
Zeldin, Darryl (NIEHS)
Applications
Therapeutics
Research Materials
Therapeutic Areas
Cardiology
Research Products
Animal Models
Lead IC
NIEHS
ICs
NIEHS
This technology includes EPHX1/EPHX2 null mice and showed that disruption of both EPHX1 and EPHX2 almost completely abolished hydrolysis of several EETs which can be used in the treatment of cardiovascular diseases. EPHX 1 is significantly involved in EET hydrolysis, and we believe the combined use of EPHX1 and EPHX2 inhibitors would provide a better alternative to currently available therapeutic options or the EPHX2-based therapies currently in trials for the treatment of cardiovascular diseases.
Commercial Applications
- The products that could be made are selective inhibitors of EPHX1 or inhibitors of both EPHX1 and EPHX2 as therapies for the treatment of many cardiovascular diseases.
- EPHX1 or EPHX1/2 inhibitors could be used as pharmaceutical drugs in humans and animals or used for research purposes.
Competitive Advantages
Dual inhibition of EPHX1 and EPHX2 should potentiate the effects of endogenous EETs more than EPHX2 inhibition alone.
Licensing Contact: